The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive ...

Appendectomy may be a useful addition to medical therapy for preventing relapse of ulcerative colitis among patients in ...

AbbVie  today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe ...

Infliximab (Remicade) and adalimumab (Humira) are the only biologics approved for children with IBD; vedolizumab is often prescribed off-label ... for Sick Children, Ferring, AbbVie, Takeda ...

In total, the open-label, phase 3 study plans to enroll 25 patients with ... vice president and head of global research and medical for uro-oncology and urology at Ferring Pharmaceuticals, in the news ...

First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ADSTILADRIN as the new standard of care and backbone therapy for non ...

Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “For Ferring, this was a year of both continuity and change as we drew on the company’s strengths while evolving our approach ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in ...

Commitment to sustainability highlighted by supply of 1.5 million doses of Carbetocin Ferring (carbetocin, room temperature-stable formulation) to reduce maternal deaths in low- and lower-middle ...